<DOC>
	<DOCNO>NCT02742987</DOCNO>
	<brief_summary>CLOTILDIA single-center , prospective , randomize , open label , cross-over study evaluate effect ticagrelor versus high-dose clopidogrel endothelial function platelet reactivity patient type-2 diabetes mellitus ( T2DM ) treat percutaneous coronary intervention ( PCI ) .</brief_summary>
	<brief_title>Clopidogrel Versus Ticagrelor Type-2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>type 2 diabetes mellitus stable coronary disease coronary revascularization PCI least 1 month prior recruitment acute coronary syndrome platelet count &lt; 70x109/l active bleed bleed diathesis history intracranial bleed gastrointestinal bleeding &lt; 6 month cerebrovascular accident &lt; 3 month history malignancy concomitant need oral anticoagulant therapy severe liver disease chronic renal failure ( glomerular filtration rate &lt; 30 ml/min /1.73m2 )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>